Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 8/20 | 0.39 |
| ▸ | MGLL | Q99685 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14749775 | 0.88 | DGAT1 (0.40) | DGAT1MGLLMAPTTDP1KDM4E | |
| SCHEMBL14750025 | 0.85 | MGLL (0.41) | DGAT1MGLL | |
| SCHEMBL14750014 | 0.75 | CYP4F2 (0.35) | MGLLMAPTMAPK1MEN1KMT2A | |
| SCHEMBL14749776 | 0.75 | L3MBTL1 (0.42) | MAPTMEN1KMT2A | |
| SCHEMBL14750029 | 0.71 | CYP2C9 (0.55) | DGAT1MAPTTDP1KDM4EALOX15 | |
| SCHEMBL30364533 | 0.68 | MAPT (0.46) | MAPTTDP1KDM4EALOX15MAPK1 | |
| SCHEMBL12584714 | 0.68 | MAPT (0.46) | MAPTTDP1KDM4EALOX15MAPK1 | |
| SCHEMBL14749736 | 0.68 | ALDH1A1 (0.48) | KDM4EMEN1KMT2A | |
| SCHEMBL4464655 | 0.68 | BRD4 (0.37) | MAPTMEN1KMT2A | |
| SCHEMBL20482392 | 0.66 | ALDH1A1 (0.51) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059853-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059853-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE4A | DGAT1 942/4885MGLL 254/4885MAPT 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.